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Abstract
In the last few years, the development of a plasmid-based reverse genetics system for mammalian
reovirus has allowed the production and characterization of mutant viruses. This could be 
especially significant in the optimization of reovirus strains for virotherapeutic applications, 
either as gene vectors or oncolytic viruses. The genome of a mutant virus exhibiting increased 
sensitivity to interferon was completely sequenced and compared with its parental virus. Viruses 
corresponding to either the parental or mutant viruses were then rescued by reverse genetics and 
shown to exhibit the expected phenotypes. Systematic rescue of different viruses harboring either
of the four parental genes in a mutant virus backbone, or reciprocally, indicated that a single 
amino acid substitution in one of λ2 methyltransferase domains is the major determinant of the 
difference in interferon sensitivity between these two viruses.
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Introduction
Mammalian reoviruses are among a plethora of viruses that are presently under investigation for 
their ability to preferentially infect and destroy transformed/cancer cells. This has led to recent 
progress in their clinical use against various forms of human cancers (briefly reviewed among 
others by: Kelly et al., 2009; Black and Morris, 2012). In contrast to most other “oncolytic” 
viruses presently under consideration for clinical use, reoviruses are naturally oncolytic and have 
not been submitted to genetic manipulation for their clinical use. In fact, it was not possible until 
recently (Kobayashi et al., 2007) to easily manipulate the reovirus genome using a plasmid-
based reverse genetics system.
The initial observations that led to the utilization of reovirus as an “oncolytic” virus 
suggested that a decreased activity of the interferon-inducible double-stranded RNA-dependent 
protein kinase (PKR), which occurs upon Ras-induced cell transformation, was responsible for 
the preferential infection and destruction of cancer cells by reovirus (Strong et al., 1998). 
Despite the fact that multiple steps of the reovirus replicative cycle are likely involved in 
preferential replication and virus-induced cancer cell death (Lemay et al., 2007; Marcato et al., 
2007), further work has supported the idea that a lower induction of interferon in Ras-
transformed cells favors viral propagation and could be of major importance to the virus' 
oncolytic activity (Shmulevitz et al., 2010).
To further support the idea that interferon-induced antiviral pathways are critical in the 
ability of reovirus to discriminate between parental and Ras-transformed cells, a mutant virus 
obtained by chemical mutagenesis was selected for its increased sensitivity to interferon and was 
actually shown to exhibit a more complete blockage than the wild-type virus in parental cells, 
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even at extremely high multiplicity of infection (Rudd and Lemay, 2005).
Multiple reovirus genes are suspected to be involved in the control of the interferon innate
immune response (Sherry, 2009; Sherry et al., 2009). The μ2 protein was shown to be the major
determining factor in the control of interferon signaling induction by altering the subcellular 
localization of IRF-9 (Irvin et al., 2012; Zurney et al., 2009). The σ3 protein could rather affect 
interferon sensitivity due to its ability to sequester the dsRNA activator of the interferon-
inducible protein kinase PKR; however, this property of σ3 could be modulated by μ1 since the 
σ3-μ1 heterohexamer does not appear to bind dsRNA (Schiff, 2008). Finally, at least in some cell
types, the σ2 and λ2 protein were previously suspected to play a role in the control of either 
induction of interferon signaling or virus' sensitivity to interferon (Sherry et al., 1998).
In order to clarify which genetic determinants are involved in the large difference in 
interferon sensitivity between the parental and previously identified P4L-12 mutant virus (Rudd 
and Lemay, 2005), the complete sequence of the viral genome was determined. Both viruses 
were then reconstructed by site-directed mutagenesis and reverse genetics, since a number of 
differences were observed between the isolate used to construct the reverse genetics plasmids and
the parental laboratory stock initially used to isolate the mutant virus. Each four genes exhibiting 
differences between the parental and mutant viruses were then individually substituted either to 
replace the mutant gene by its parental counterpart or replacing the parental gene by its mutant 
counterpart in the parental background. This clearly demonstrated that the single amino acid 
substitution in one of the two methyltransferase domains of λ2 is the major determinant of the 
difference in interferon sensitivity between these two viruses.
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Results
Sequencing of the interferon-sensitive P4L-12 mutant
In order to determine the differences in sequence between the interferon-sensitive P4L-12 
mutant (Rudd and Lemay, 2005) and the original wild-type type 3 Dearing (T3D) 
(T3/Human/Ohio/Dearing/55) from which it was derived, the whole coding sequence of the 
genome was analyzed by RT-PCR on the semi-purified viral genome from both the mutant and 
wild-type laboratory stocks, followed by direct sequencing of the PCR products, as described in 
Materials and Methods and previously used in the laboratory (Jabre et al., 2013).
Despite the fact that the P4L-12 mutant was obtained following treatment with a high 
dose of the chemical mutagen nitrosoguanidine (Rudd and Lemay, 2005), only 4 genes were 
found to exhibit nonsynonymous mutations compared to the wild-type resulting in a total of 6 
amino acids substitutions (Table 1). Of these, only the λ2 T636M, μ1 P315S and σ3 M221I are 
unique among currently available sequences of T3D (Table 2 and data not shown) and were thus
of special interest. Six additional silent nucleotide substitutions were also found between the 
wild-type and mutant virus (GeneBank accession numbers KP208804 to KP208813 for the wild-
type and KP208814 to KP208823 for P4L-12 mutant).
Sequence comparison of different stocks of wild-type reovirus type 3 Dearing
The complete sequences obtained were also compared with that of the wild-type virus 
encoded by the 10 plasmids of the reverse genetics system (Kobayashi et al., 2007) and at least 
one amino acid change between the two wild-type viruses was found in seven out of eleven 
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proteins; the only completely identical proteins were σ2, σ3, σNS and σ1s. This is not the first 
time that such differences were observed between laboratory stocks of so-called reovirus type 3 
Dearing (Coffey et al., 2006; Nygaard et al., 2013; Yin et al., 2004), this has even lead to the 
designation of subtypes such as T3DF (from Fields' laboratory), T3DN (from Nibert's laboratory) 
and T3DC (from Cashdollar's laboratory). Thus, for sake of simplicity, the laboratory virus stock 
used in the present study will be referred to as T3DS (Sandekian) while the wild-type virus 
rescued from the plasmids originally obtained from Kobayashi and Dermody will be referred to 
as T3DK (Kobayashi). In addition to the 12 amino acid substitutions, 11 silent nucleotide 
substitutions between the two viruses were also found (data not shown).
Comparative sequence analysis was also performed with the sequence of another 
complete T3D genome (referred to as T3DW) that was used in a recent study by another group 
(van den Wollenberg et al., 2012) and the sequence of another laboratory stock deposited in the 
NCBI database by one further group (referred to as T3DH); finally the sequence of the virus 
currently used in oncolytic virotherapy under the tradename “REOLYSIN®” was added to the 
comparison (Chakrabarty et al., 2014). Only complete sequences determined by direct 
sequencing of the viral genome were retained for this analysis since it is difficult to assume that 
sequences obtained earlier from cloned viral genes are necessarily representative and that they 
would actually generate a replication-competent virus when combined together.
The laboratory subtype, T3DS, did not display any more differences from T3DK when 
compared to other completely sequenced genomes. While some positions are clearly more 
variable, all stocks showed the presence of 8 to 19 differences including 2 to 8 unique 
substitutions compared to T3DK.  It thus seems that each stock, or subtype, has its own sequence 
“signature” and that T3DS with 12 amino acid differences including only 3 unique substitutions is
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not more divergent from T3DK than other virus stocks currently in use in different laboratories.
Reverse genetics rescue of viruses harboring single-gene substitution
In order to determine which of the amino acids differences between T3DS and P4L-12 
viruses are responsible for the difference in interferon sensitivity between the two viruses, site-
directed mutagenesis was used to introduce the changes in the reverse genetics plasmids encoding
the different proteins; when more than one change was found on the same protein, the 
corresponding nucleotide changes were all introduced on the same plasmid. Since the parental 
T3D (T3DS) used to isolate P4L-12 differs from the plasmid-encoded T3DK sequence, a complete
set of plasmids encoding “wild-type” T3DS was first constructed and then further subjected to 
site-directed mutagenesis to obtain P4L-12 encoding sequences.
Both a parental T3DS and P4L-12 virus were rescued by transfection of the corresponding 
plasmid combination. Viruses were similarly obtained using one P4L-12 gene (L2, M2, M3 and 
S4) in a background of nine T3DS genes. All these viruses were rescued and propagated, as 
described in Materials and methods. Reciprocally, viruses harboring one T3DS gene in a 
background of nine P4L-12 genes were also rescued and propagated.
The infectivity and replicative ability of these different viruses was then examined. L929 
cells were infected at a multiplity of infection of 2 TCID50 units per cell and viral proteins in 
infected cells were first examined by immunoblotting (Fig.1A); this was a first indication that all 
viruses were able to infect with a similar efficiency since there were no apparent differences in 
the amount of viral proteins produced. Production of infectious virus was next examined by 
infecting cells and measuring the fold-increase of infectious virus (Fig. 1B). In either the T3DS or 
P4L-12 background, all viruses harboring substitution of single genes from the other virus did not
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appear to be significantly different from their background virus. In the T3DS background a small 
increase (up to approximately sixfold for the S4 substitution) was observed while in the P4L-12 
background a twofold increase for observed for M2 and twofold decrease for S4. Overall, there 
was thus no apparent significant defects when single genes were substituted in either background.
Interferon sensitivity of rescued viruses
Having established that the different rescued viruses can replicate to similar levels in the 
absence of interferon, their interferon sensitivity was then examined in comparison with their 
respective parental viruses.
Interferon sensitivity was first examined by measuring the titer reduction on L929 cells 
treated at a fixed, near saturating, β-interferon concentration (200 international units/ml), as 
described in Materials and methods. As expected, rescued T3DS harboring none of the P4L-12 
genes exhibited resistance to interferon, its titer being almost unaffected at 200 international 
units/ml of interferon while rescued P4L-12 showed close to a hundred-fold decrease of its titer 
(Fig. 2). These values are comparable with those routinely obtained with the two parental viruses 
in previous experiments (data not shown).
Substitution of T3DS genes encoding either μNS or μ1 of P4L-12 only slightly increased 
sensitivity to interferon by less than tenfold while σ3 had no effect (Fig. 2). However, 
substitution of the L2 gene encoding λ2 significantly increased the interferon sensitivity 
rendering the virus as sensitive as the P4L-12 virus.  The reciprocal experiment where single 
genes from T3DS were singly substituted in the P4L-12 background confirmed that λ2 by itself is 
sufficient to render the virus as resistant as T3DS while other proteins had only a slight (μNS) or 
essentially no effect (μ1 and σ3) on interferon sensitivity (Fig. 2).
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It appears very unlikely that differences in residual interferon in the viral inocula could 
affect the results, given the freeze-thaw treatment, dilutions used, and the fact that there was no 
differences in interferon induction between T3DS and P4L-12. However, in order to further ruled 
out this possibility, infectious T3DS, P4L-12 and single L2 reassortant viruses were recovered 
from human HeLa cells before being titrated on murine L929 cells in the presence or absence of 
murine interferon; in these conditions any interferon from virus inoculum will be of human 
origins and will not act on murine cells used in the interferon assay. Identical results were 
obtained, correlating the presence of L2 from P4L-12 with interferon sensitivity (data not shown).
The interferon sensitivity of the same viruses was then further examined using serial 
binary dilutions of interferon in 96-multiwell plates that were then stained and quantitated (Fig. 
3A). When the rescued T3DS virus and viruses harboring a single P4L-12 gene in this background
was examined (left panel), the effect of λ2 was again evident, especially at intermediate 
concentrations of interferon (approximately 10 to 50 IU/ml) while μNS and σ3 had no effect. In 
this assay, at lower interferon concentrations compared to figure 2, the μ1 protein of P4L-12 also 
increased interferon sensitivity.
When viruses harboring single T3DS genes in a P4L-12 background were similarly 
analyzed (Fig.3A, right panel), only λ2 clearly affected interferon sensitivity, rendering the virus 
as resistant to interferon as T3DS. The increased interferon sensitivity conferred by M2 of P4L-12
in the T3DS background was not reciprocal; therefore it was not further examined in the present 
study.
Altogether, the effect of λ2 was thus most striking and this gene appears to be the main 
and most likely the only determinant of the difference in interferon sensitivity between T3DS and 
P4L-12, its presence being clearly sufficient to reconstitute the respective phenotype of the two 
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viruses. A representative multiwell plate is presented (Fig.3B) comparing the original T3DS and 
P4L-12 virus with their corresponding rescued virus and those where the L2 gene was singly 
substituted.
Expression of the λ2 protein in infected cells
In order to rule out the possibility that there is a difference in the amount of λ2 present in 
the infected cells during infection by T3DS or P4L-12, immunoblotting was performed on the 
rescued viruses harboring all the genes of either viruses, as well as on the viruses harboring solely
the λ2 protein of the other virus (T3DS background with λ2 of P4L-12 and reciprocally). The 
amount of λ2 protein in each case was compared with that of the major outer capsid protein μ1. 
There was no apparent difference between these four viruses (Fig.3C) and a simple change in λ2 
expression or stability is thus unlikely.
Discussion
The present study illustrates that the state-of-the-art plasmid-based reverse genetics 
approach can be successfully used to study and completely reconstruct virus mutants previously 
identified by the use of more classical genetic techniques such as chemical mutagenesis. This has 
allowed to identify polymorphic amino acids residues in the mammalian orthoreovirus genome as
well as clearly pinpoint an amino acid substitution that can drastically affect the interferon 
sensitivity of viral strains. As previously mentioned, the λ2 protein was previously identified by 
classical reassortment studies as a possible molecular determinant of the control of interferon 
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response in reovirus-infected cells; however, this is the first time that this has been firmly 
established using a completely defined genetic system. Interestingly, an immunoreceptor 
tyrosine-based activation motif (ITAM) that could affect interferon signaling pathways in some 
cell types, is observed in λ2, although there is currently no evidence that it is actually functional 
(Stebbing et al., 2014). The amino acid substitution in P4L-12 is not part of this ITAM motif.
The threonine at position 636, substituted for a methionine in P4L-12, is a conserved 
residue in the λ2 protein sequence of different virus strain (Table 2) (Breun et al., 2001) and is 
located in one of the two methyltransferase domains (Reinisch et al., 2000; Breun et al., 2001; 
Bujnicki and Rychlewski, 2001). It is still not firmly established if this first methyltransferase 
domain is responsible for N-7 or the subsequent 2'-O methylation of the cap structure. However, 
sequence comparisons suggest the latter possibility (Bujnicki and Rychlewski, 2001) and is also 
consistent with the relative order of the two methyltransferase domains in Cypovirus (Zhu et al., 
2014), another double-stranded RNA virus of the Reoviridae family. Methylation of the RNA cap
structure, especially at the 2'-O position could be of importance to avoid recognition of viral RNA
as nonself. It could thus affect either induction of interferon signaling or sensitivity to interferon-
induced antiviral proteins, such as IFIT1 (recently reviewed by: Hyde and Diamond, 2015). This
aspect has been especially well studied in members of the Flaviviridae family but has also been 
noticed in such different viruses as coronaviruses, vesicular stomatitis virus and 
metapneumovirus (Daffis et al., 2011; Zust et al., 2011; Habjan et al., 2013; Kimura et al., 
2013; Dong et al., 2014; Kindler and Thiel, 2014; Ma et al., 2014; Menachery et al., 2014). 
An altered 2'-O methyltransferase activity of λ2 could thus potentially explain the altered 
interferon resistance of P4L-12 compared to the parental virus. Interestingly, in rotavirus, another
member of the Reoviridae family, the capping enzyme VP3 was shown to act as an antagonist of 
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innate immunity (Zhang et al., 2013) and it was proposed that variations in the efficiency of the 
capping reaction, more specifically that of methyltransferase activity, should be examined to 
determine if it could affect the ability of the virus to control the innate immune reaction (Arnold 
et al., 2013; Ogden et al., 2014). It will be of interest to perform similar studies with the λ2 
protein of reovirus.
Previous work has established the μ2 protein as the major determinant of the extent of 
interferon signaling following reovirus infection (Zurney et al., 2009; Irvin et al., 2012; 
Stebbing et al., 2014). When interferon induction by T3DS and P4L-12 was compared by 
recovering supernatant from L929-infected cells (data not shown), both of these supernatants 
were able to similarly protect cells against the unrelated murine encephalomyocarditis virus 
(EMCV), as used in previous studies (Sandekian et al., 2013). This is well in accordance with 
the fact that there is no difference in the μ2 protein of the two viruses and thus probably no 
significant differences in induction of either interferon or interferon-induced genes. Furthermore, 
it should be stressed that the presence of a proline at position 208 indicates that these viruses are 
relatively, although not completely, efficient at repressing interferon signaling (Irvin et al., 2012;
Stebbing et al., 2014) suggesting that their difference rather resides in differences of sensitivity 
to interferon-induced antiviral mechanisms.
The results presented herein thus further support the idea that multiple reovirus proteins 
are involved as determinants of reovirus' sensitivity to interferon either by differences in the 
modulation of interferon signaling or differences in the sensitivity of the interferon-induced 
antiviral effectors. In this study the λ2-encoding gene, L2, appears as the major determinant of 
the difference between T3DS and P4L-12. The importance of multiple regulatory mechanisms 
directed against the interferon innate immune response has also been demonstrated in rotavirus 
Page 12 of 28
(Arnold et al., 2013), another member of the Reoviridae, and in other unrelated viruses such as 
the large DNA virus vaccinia (Perdiguero et al., 2009) as well as important human RNA viruses 
such as hepatitis C (Qashqari et al., 2013) and influenza virus (Garcia-Sastre, 2011).
There are numerous evidence suggesting induction of interferon antiviral response or 
virus' sensitivity to this response is critical in the differential ability of a virus to replicate in, and 
kill, different cell types. As described in the introduction, this is also likely critical in reovirus' 
oncolytic ability. The possibility of modulating both the level of interferon signaling and 
sensitivity of reovirus strains to antiviral interferon-induced genes, by a combination of various 
mutations in either σ3, μ2 and λ2, could certainly contribute to further optimization of viral 
strains for infection and killing of different cancer cell types.
Materials and methods
Cell lines and viruses
L929 mouse fibroblasts were originally obtained from the American type culture 
collection (ATCC® CCL-1™). The baby hamster kidney cell line (BHK) stably expressing the 
T7 RNA polymerase has been described (Buchholz et al., 1999) and was a generous gift from the
laboratory of Dr John Hiscott (Lady Davis Research Institute, Montréal, Canada). Both cell lines 
were grown in minimal Eagle medium (MEM) with 5% fetal bovine serum.
Wild-type reovirus type 3 Dearing (T3/Human/Ohio/Dearing/55) was originally obtained 
from the American Type Culture Collection (Reovirus 3, ATCC® VR824™). The laboratory 
stock was derived from a pure plaque after one passage of the original stock on L929 cells. This 
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laboratory virus stock was thereafter used between passage 3 and 5 at a low multiplicity of 
infection.
Sequencing of the whole viral genomes
Viral genomic RNA was prepared and fragments for sequencing were generated by RT-
PCR, as previously described (Brochu-Lafontaine and Lemay, 2012), except that Vertrel was 
used to prepare reovirus virions (Mendez et al., 2000). The sequences corresponding to all ten 
genes of the wild-type laboratory stock were deposited under accession numbers KP208804 to 
KP208813 in GenBank. The sequences corresponding to all ten genes of the reovirus interferon-
sensitive P4L-12 mutant are accessible under numbers KP208814 to KP208823.
Accession numbers for sequences used for comparisons are EF494435 to EF494444 in the
nucleotide database for T3DK; ADJ00316 to ADJ00325 in the protein database for T3DH; and 
GU991659 to GU991668 for T3DW in the nucleotide database. The sequence of REOLYSIN® 
was deduced from the differences noticed between each of the genes and its reference sequence 
as described (Chakrabarty et al., 2014).
Reverse genetics
The plasmids separately harboring each of the cDNA corresponding to the 10 genes of 
reovirus serotype 3 Dearing, under the transcriptional control of the T7 promoter, as previously 
described (Kobayashi et al., 2007), were obtained from the laboratory of Dr Terence Dermody 
(Vanderbilt University, Nashville, Tennessee). To obtain virus mutants in specific genes, the 
corresponding plasmid was directly submitted to site-directed mutagenesis and used to recover 
infectious virus by transfection in BHK cells expressing the T7 RNA polymerase and rescued 
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viruses were propagated. Kinetics of viral replication and viral titers were assessed as previously 
described (Brochu-Lafontaine and Lemay, 2012).
Immunoblotting
Infected cells were recovered by scraping in a small volume of medium and processed for 
immunoblotting, as previously described (Brochu-Lafontaine and Lemay, 2012). 
Immunoblotting was performed using monoclonal antibodies directed against either σ3 (4F2), λ2 
(7F4) or μ1 (10F6) (Virgin et al., 1991). Images were obtained using either autoradiography on 
Kodak BioMax Light films or on a Typhoon Trio™ imager (GE Healthcare Life Sciences).
Determination of interferon sensitivity
Interferon sensitivity was determined by two different approaches. The reduction of titer 
assay was first used as previously described (Danis et al., 1997). Briefly, L929 cells were seeded 
in 96-well plates and were either left untreated or pre-treated with 200 international units (IU)/ml 
of mouse β-interferon (PBL InterferonSource) for 24 hours before being used in virus titration by 
TCID50. Following virus adsorption, interferon was added back to the pre-treated plate and the 
reduction in virus titer in interferon-treated cells compared to untreated cells was determined 7 
days post-infection.
To measure sensitivity of viruses to different concentrations of interferon, serial twofold 
dilution of interferon in 96-well plates was done followed by infection with the different virus 
strains at the same multiplicity of infection. Plates were stained with methylene blue as 
previously described (Sandekian et al., 2013); images were obtained and quantitated using an 
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AlphaImager HP image analyzer.
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Figure legends:
Fig. 1. Infectivity and replication of the different rescued viruses. L929 cells were infected at a 
MOI of 2 TCID50 units/cell. Results for the different viruses harboring either none or single P4L-
12 genes in a T3DS background or none or single T3DS genes in a P4L-12 background are 
presented.  (A) Proteins were recovered from infected cells at 24 hours and analyzed by 
immunoblotting using an anti-σ3 monoclonal antibody, as described in Material and Methods. (B)
Infected cells were recovered at either 24 or 48 hours post-infection. Cells were disrupted by 
three cycles of freeze-thaw (-80°C to room temperature) and virus titration was performed by 
TCID50 on L929 cells in 96-well microplates. Results, on a logarithmic scale with error bars 
representing standard error of the mean, are presented as the average fold-increase in two distinct 
experiments at 24 hours, 48 hours, and with all four data points combined, as indicated.
Fig. 2. Interferon sensitivity of the different rescued viruses. The different rescued viruses, as in 
figure 1, were titrated using a TCID50 assay in the absence or presence of 200 IU/ml of murine β-
interferon, as described in Material and methods. Average fold-reduction in virus titers for 
independent experiments for each sample is presented on a logarithmic scale with error bars 
indicating the maximal value observed for each virus (n=5 for the parental viruses, n=3 for the 
two viruses harboring substitution of the L2 gene and n=2 for the other viruses). In both the T3DS
and P4L-12 background, only L2 gene substitution statistically altered interferon sensitivity, at 
p=0.002 and p=0.05 respectively using unpaired Student's t-test.
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Fig. 3. Effect of different doses of interferon on the rescued viruses. (A) L929 cells were seeded 
in 96-well microplates and were infected 24 hours later at a MOI of 0.05 TCID50 unit/cell with 
the different rescued viruses. Following the one-hour adsorption period at 4°C, serial twofold 
dilutions of interferon were added to each well, as indicated. Cells were incubated 3 days before 
being fixed, stained with methylene blue, and quantified as described in Materials and methods. A
representative experiment out of three independent experiments is presented. (B) Representative 
microwell plate comparing the two original T3DS and P4L-12 viruses with rescued viruses 
rsT3DS and rsP4L-12, as well as P4L-12 harboring λ2 from T3DS, rsP4L-12-[L2-(T3DS)], and 
reciprocally T3DS harboring λ2 from P4L-12, rsT3DS-[L2-(P4L-12)]. (C) Proteins were recovered
24 hours post-infection from L929 cells infected at a MOI of 2 TCID50 unit/cell with the same 
four viruses as in panel B. Immunoblotting analysis was then performed using either anti-λ2 or 
anti-μ1 monoclonal antibody, as described in Materials and Methods.
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Wild-type (T3DS) Mutant (P4L-12) Amino acid position















Amino acids differences between wild-type reovirus type 3 Dearing laboratory
stock (T3DS) and derived mutant P4L-12 
Table 2
Amino acids differences between different reovirus type 3 Dearing



























































































































aT3D-Kobayashi, wild-type virus from the reverse genetics system (Kobayashi et al., 2007).
bT3D-Sandekian, original wild-type virus reported in this study
cT3D-Wollenberg, wild-type virus (R124) used in van den Wollenberg et al., 2012.
dT3D-Hosseini, wild-type unpublished virus sequence from NCBI database.
eT3D-Reolysin®, wild-type virus used in clinical trials as described in Chakrabarty et al., 2014.
